O
Omidreza Firuzi
Researcher at Shiraz University of Medical Sciences
Publications - 172
Citations - 5458
Omidreza Firuzi is an academic researcher from Shiraz University of Medical Sciences. The author has contributed to research in topics: Docking (molecular) & Chemistry. The author has an hindex of 33, co-authored 159 publications receiving 4240 citations. Previous affiliations of Omidreza Firuzi include University of Tabriz & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Evaluation of the antioxidant activity of flavonoids by “ferric reducing antioxidant power” assay and cyclic voltammetry
TL;DR: Indications were found that the o-dihydroxy structure in the B ring and the 3-hydroxy group and 2,3-double bond in the C ring give the highest contribution to the antioxidant activity.
Journal ArticleDOI
Antioxidant Therapy: Current Status and Future Prospects
TL;DR: Recent human studies exploring the efficiency of antioxidants in prevention and treatment of various diseases are reviewed and some suggestions are provided to be considered if antioxidant therapy is to succeed as an effective therapeutic strategy.
Journal ArticleDOI
Modulation of neurotrophic signaling pathways by polyphenols
TL;DR: A better understanding of the neurotrophic effects of polyphenols and the concomitant modulations of signaling pathways is useful for designing more effective agents for management of neurodegenerative diseases.
Journal ArticleDOI
5-Lipoxygenase gene disruption reduces amyloid-β pathology in a mouse model of Alzheimer’s disease
TL;DR: In vitro studies establish for the first time a novel functional role for 5LO in the pathogen‐esis of AD‐like amyloidosis, thereby modulating γ‐secretase activity.
Journal ArticleDOI
2H-chromene derivatives bearing thiazolidine-2,4-dione, rhodanine or hydantoin moieties as potential anticancer agents.
Mohammad Azizmohammadi,Mehdi Khoobi,Ali Ramazani,Saeed Emami,Abdolhossein Zarrin,Omidreza Firuzi,Ramin Miri,Abbas Shafiee +7 more
TL;DR: Hydantoin derivative 6o with a 6-bromo-2-methyl-2H-chromene substructure showed the best profile of cytotoxicity comparable to that of cisplatin as standard anticancer agent.